SRRK250117P12500
- 0.05
- 0.000.00%
Scholar Rock Newsroom
Truist Financial Initiates Scholar Rock(SRRK.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Scholar Rock Highlights Upcoming Priorities For 2025; Says BLA And MAA Submission For Apitegromab In SMA On Track For Q1
Express News | Scholar Rock Holding Corp - Initiating Phase 2 Opal Trial in Sma Patients Under Two Years Old in Mid- 2025
Express News | Scholar Rock Holding Corp -Filing of Ind Application for Srk-439 on Track for 3Q 2025
Express News | Scholar Rock Highlights 2025 Strategic Priorities
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Scholar Rock(SRRK.US) 10% Shareholder Sells US$15.76 Million in Common Stock
$Scholar Rock(SRRK.US)$ 10% Shareholder Invus Public Equities, L.P. sold 409.43K shares of common stock on Nov 25, 2024 at an average price of $38.4865 for a total value of $15.76 million. This
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50
Scholar Rock Holding Is Maintained at Buy by HC Wainwright & Co.
Promising Market Dynamics and Growth Potential for Scholar Rock's Apitegromab Boost Buy Rating
Express News | Scholar Rock Holding Corp : H.c. Wainwright Raises Target Price to $50 From $40
U.S. Small Caps Rise; Scholar Rock Holding Climbs Highest